Neotron now able to detect nitrosamines in APIs and drugs
The European Medicines Agency (EMA) recently issued advice to pharmaceutical companies on how to avoid the presence of nitrosamines in medicines. Nitrosamines are classified as probable human carcinogens and the EMA has asked manufacturers of medicines made with chemically synthesized active pharmaceutical ingredients (APIs) to test their products for the possible presence of such impurities.
In response to this crisis and in support of the pharmaceutical industry, Neotron Pharma GMP Lab, part of the Cotecna Group, has developed an effective analytical method which can detect nitrosamines in APIs and drugs.
To learn more, please download the full report published by Neotron, or contact customerservice.pharma@neotron.it
Latest News
24.04.2024
Non-Destructive Testing Methods for Assessing Concrete Integrity
A comprehensive exploration of advanced non-destructive testing techniques for concrete integrity assessment conducted by Wimpey Laboratories.
23.04.2024
Agronômica opens a new laboratory in Santos, Sao Paulo, Brazil.
On April 11th, Agronômica inaugurated the new laboratory unit in Santos, Sao Paulo, Brazil, focusing on molecular, biochemical and morphological methods of analysis.